



For more information:
Investor Relations (Tel: +34 91 244 44 22)
Marta Campos Martínez mcampos@rovi.es
Virginia Pérez Repes vperez@rovi.es

ROVI announces the upcoming exclusive commercialization of Medicebran® and Medikinet® in Spain

Madrid, 27th of November, 2013 – Laboratorios Farmacéuticos Rovi, S.A. (ROVI or the “Company”) announces it has signed an agreement with MEDICE Arzneimittel Pütter GmbH & Co. KG (“Medice”) to market in Spain Medicebran® and Medikinet®, products indicated for the treatment to ADHD (Attention Deficit Hyperactivity Disorder) in children and teenagers.

Under this marketing agreement, ROVI will be in charge of the promotion, distribution and sales, on exclusivity basis, for both Medicebran® and Medikinet®, psychostimulant drugs aimed for the treatment of ADHD in children and teenagers between 6 and 18 years of age. Both products contain the active ingredient hydrochloride methylphenidate; the difference is that Medicebran® is an immediate-release drug while Medikinet® has a modified release (50% of the dose has immediate release and the other 50% extended release).

These drugs enhance the activity of certain parts of the brain that have low activity, helping to improve the level of attention and the capacity to focus, while reducing impulsive behaviour. Its administration is part of a comprehensive treatment program that typically includes psychological, educational and social therapy.

According to data of IMS Health, the market for psychostimulant medications for children and teenagers reached in Spain, in the 12 month period until September of 2013 (MAT September of 2013), a total figure of 47.8 million Euros, being the joint sales of Medicebran® and Medikinet® in this same period 9.6 million Euros, representing a market share of 20%.

Juan López-Belmonte Encina, Chief Executive Officer of ROVI, said that: “we are very glad with the award of this new distribution agreement, which strengthens our product portfolio in the area of pharmaceutical specialties, and, we hope, will contribute to the growth of the Group’s revenue in the coming years”.

About ROVI

ROVI is a fully integrated Spanish specialty pharmaceutical company engaged in the research, development, in-licensing, manufacturing and marketing of small molecule and specialty biologic drugs. The Company has a diversified portfolio of products that it markets in Spain through its specialized sales force, calling on specialist physicians, hospitals and pharmacies. ROVI’s portfolio of 30 principal marketed products is currently anchored by the internally-developed, second generation low molecular weight heparin, Bemiparin. ROVI’s research and development pipeline is focused primarily on the expansion of applications, indications and alternative mechanisms of action for the heparin-derived products and other glycosaminoglycans and on the development of new controlled release mechanisms based on ISMTM technology, with the aim of obtaining new pharmaceutical products that enable the regular administration of formulations which are administered daily in chronic and prolonged treatments. ROVI manufactures the active biological ingredient (Bemiparin) for its principal proprietary products and for injectable pharmaceutical products developed by its in-house research team, and utilizes its state-of-the-art filling and packaging capabilities to provide a broad array of toll manufacturing services to leading international pharmaceutical companies, primarily in the area of pre-filled syringes. In addition, ROVI provides contract manufacturing and packaging services of solid oral pharmaceutical dosage forms, using the most enhanced technology, Roller Compaction. Additional information about ROVI is available on the company’s website: www.rovi.es.